R. BRUCE BRACKEN, M.D.

Professor of Surgery
Division of Urology

Education:
1959-1962 - M.D. - University of Manitoba, Winnipeg, Manitoba

1962-1966 - Internship - University of Manitoba, Winnipeg, Manitoba

1966-1970 - Surgical Resident - Montreal General Hospital, Montreal, Quebec; and Winnipeg General Hospital, Winnipeg, Manitoba

1970-1973 - Urology Resident - University of Michigan, Ann Arbor, Michigan

1973-1974 - Fellowship in Oncology - Memorial Hospital for Cancer and Allied Diseases, New York, New York

Board Certification:
American Board of Urology

LICENSED:  Ohio  #35-046750

ACADEMIC APPOINTMENTS:

1984-Present - Professor of Surgery, University of Cincinnati Medical Center, Cincinnati, Ohio

1984-1998 - Director, Division of Urology, University of Cincinnati Medical Center, Cincinnati, Ohio

1981-1984 - Associate Professor of Surgery, Division of Urology, University of Cincinnati, Medical Center, Cincinnati, Ohio

1977-1981 - Associate Professor of Urology, Department of Urology, The University of Texas M.D. Anderson Hospital & Tumor Institute, Houston, Texas

1974-1977 - Assistant Professor of Surgery, Department of Surgery, The University of Texas M.D. Anderson Hospital & Tumor Institute, Houston, Texas

MAJOR SCIENTIFIC INTEREST: Urologic Oncology

HOSPITAL APPOINTMENTS:

Active Staff - University of Cincinnati Hospital
Consulting Staff: - Cincinnati Children’s Hospital Medical Center
Consulting Staff - The Veterans Affairs Medical Center
Courtesy Staff - The Drake Center, Inc.
Courtesy Staff - The Christ Hospital
Courtesy Staff - Good Samaritan Hospital
Courtesy Staff - The Jewish Hospitals

PROFESSIONAL SOCIETIES:

Cincinnati Urologic Society, 1981-present
Ohio Urological Society, 1983-present (President 1992 -1993)
American Urological Association, Inc., 1984-present
North Central Section of American Urological Association, 1981-present (President 2002; Executive Board Member 1995-1998)
Fellow of the Royal College of Physicians and Surgeons of Canada in Urology, 1973-present
Certificate of the Royal College of Physicians and Surgeons of Canada in Urology, 1973-present
Reed Nesbit Society, 1974-present
American Board of Urology, 1975-present
Society of Urologic Oncology, 1986-present
Canadian Urological Association, 1988-present (Executive Board Member, 1995 - present)

PHD DISSERTATION COMMITTEE MEMBER

+Gz Acceleration Loss of Consciousness:  Use of G-suit Pressurization and Sensory Stimulation to Enhance Recovery.  Submitted to the Human Factors and Ergonomic Society.  Lloyd D. Tripp, Air Force Research Laboratory, Wright Patterson AFB, Ohio October 2007

EXPERT  REVIEWER

Urology, 1992 to present
Urologic Oncology, 1995 to present

BOOKS

Bracken RB and McKay, eds.  Atlas of Bladder Pathology. Igaku-Shoin Medical Publishers, Inc., New York, NY, 1991 .

PUBLICATIONS

Bracken RB,  and Diokno AC.  Melanoma of penis and urethra:  Two case reports and a review of the literature.  J Urol, 1974; 111:198-200.

Bracken RB,  and Grabstald H.  Bladder carcinoma involving the lower abdominal wall.  J Urol, 1975; 114:715-21.

Goldstein HM, Medellin H, Wallace S, Ben Menachem Y, Bracken RB, and Johnson DE. Transcatheter embolization of renal cell carcinoma:  Preliminary observations and results.  Amer J Roentg Radium Ther and Nuclear Med, 1975; 123:557-62.

Bracken RB, Johnson DE, Goldstein HM, Wallace S, and Ayalo AG.  Percutaneous transfemoral renal artery occlusion in patients with renal carcinoma:  A preliminary report.  Urology, 1975; 6:6-10.

Bracken RB, Johnson DE, and Samuels ML.  Alpha fetoprotein determinations in tumors of the testis.  Urology, 1975; 6:382-4.

Johnson DE, Schoenwald MD, Bracken RB, and Jesse R.  Rotational skin flaps to cover wound defects in the groin.  Urology, 1975; 6:461-3.

Johnson DE, Bracken RB, and Blight EM.  Proceedings of the Kimbrough Urological Seminar, 1975; IX:150-3.

Bracken RB, Schellhammer P, McSweeney J, and Whitmore WF.  The use of spermatic cord lymphatics in the relief of surgically created lower extremity edema:  A preliminary report of experiments in dogs. Invest Urol, 1975; 14:225-8.

Johnson DE, Bracken RB, Goldstein H, and Wallace S.  Percutaneous transfemoral renal artery occlusion in patients with renal carcinoma.  Proceedings of the Kimbrough Urological Seminar, 1975; IX:123-8.

Bracken RB, Blight EM, and Johnson DE.  Malignant melanoma of the genitourinary tract.  In:  Neoplasms of the Skin and Malignant Melanoma.  Yearbook Medical Publishers, Inc.., Chicago, Ill.; 1976:431-442.

Johnson DE, Bracken RB, and Blight EM.  Prognosis for pathologic Stage I non-seminomatous germ cell tumors of the testis managed by retroperitoneal lymphadenectomy. J Urol, 1976; 116:63-5.

Bracken RB, Johnson DE, Miller LS, Ayala AG, and Rutledge R.  Primary carcinoma of the female urethra.  J Urol, 1976; 116:118-92..

Bracken RB, Johnson DE.   Sexual function and fecundity after treatment for testicular tumors.  Urology, 1976; 7:35-8.

Johnson DE, Bracken RB, Ayala AG, and Samuels ML.   Retroperitoneal lymphadenectomy as adjunctive therapy in selected cases of advanced testicular carcinoma.  J Urol, 1976; 116:66-8.

Zarnosa J, Bracken RB, and Wallace S.  The radiologic features of adrenal metastases.  Urology, 1976; 13:295-99.

Schellhammer PF, Bracken RB, Bean MA, Pinsky CM, and Whitmore WF.  Immune evaluation with skin testing.  Cancer, 1976; 38:149-56.

Johnson DE, Bracken RB, Wallace S, Ayala AG, Samuels ML, Hussey DH, and Miller LS.   Urologic cancer.  In:  Cancer Patient Care at M.D. Anderson Hospital and Tumor Institute:  Clark RL and Howe CD, eds.  Yearbook Medical Publishers, Inc., Chicago, Ill.; 1976:361-414.

Handel PB, Lamy S, Bracken RB, and Johnson DE.  Treatment failure occurring after single-stage cystectomy and ileal conduit in patients with bladder carcinoma. Proceedings of the Kimbrough Urological Seminar 24th Annual Meeting, 1976; 10:46-49.

Bracken RB, Johnson DE, Rodriguez LH, Samuels ML, and Ayala AG.  Treatment of multiple superficial tumors of bladder with intravesical bleomycin.  Urology, 1977;  9(2): 161-163.

Johnson DE, Lamy S, Bracken RB.   Salvage cystectomy for radiation failure in patients with bladder carcinoma.  South Med J, 1977; 70:1279-81.

Sternberg JJ, Bracken RB, Handel PB, and Johnson DE.   Combination chemotherapy (CISCA) for advanced urinary tract carcinoma:  A preliminary report.  JAMA, 1977; 238(21):2282-87.

Bracken RB, Johnson DE, Cangir A, and Ayala AG.   Regional lymph nodes in infants with embryonal carcinoma of the testis.  Urology, 1978; 11(4):376-79.

Kouttab NM, von Eschenbach AC, Bowen JM, Bracken RB, Johnson DE and Dmochowski L.   Serum-blocking factors in human prostate carcinoma.  Cancer Bulletin, 1978; 30(4):115-18.

Kouttab NM, Bowen JM, Dmochowski L, von Eschenbach AC, Bracken RB, and Johnson DE.   Search for Type C virus-like information in normal, benign and malignant human prostatic tissues:  Proceedings of the Ninth Annual Gulf Coast Molecular Biopsy Conference.  Tex J Sci, 1978; 13:139-48.

Johnson DE, Bracken RB, Swanson DA, and Wallace S.  Arterial occlusive techniques in the management of renal disease.  Urology Update Series, 1978, Biomedia Inc., New Jersey; Vol. 1: Lesson 36.

Bracken RB, and Johnson K.  How accurate is angiographic staging of renal carcinoma?  Urology, 1979; 14:96-99.

Wallace S, Grammayek M, DeSantos LA, Murray JA, Romsdahl MM, Bracken RB, and Johnson K.   Arterial occlusion of pelvic bone tumors.   Cancer, 1979; 43:322-28.

Bracken RB, Chica GA, Johnson DE, and Luna M.   Secondary renal neoplasms:  An autopsy study.  South Med J, 1979; 72:806-11.

Samuels ML, Johnson DE, Brown B, Bracken RB, Moran MD, and von Eschenbach AC. Velban plus continuous infusion bleomycin (B3) in Stage III advanced testicular cancer: Results in 99 patients with a note on high dose velban and sequential cis-platinum.  In: Cancer of the Genitourinary Tract: Johnson DE and Samuels MD, eds.  Raven Press, New York; 1979:159-72.

Bernandino ME, DeSantos LA, Johnson DE, Bracken RB.  Computed tomography in the evaluation of postnephrectomy patients.  Radiology, 1979; 130:183-87.

Bracken RB, and Johnson DE.  Treatment of multiple superficial tumors of the urinary bladder with intravesical mitomycin C.  In:  Mitomycin C Current Status and New Developments:  Carter SK and Crooke ST, eds. Academic Press, New York, 1979:205-11.

Chan RC, Bracken RB, and Johnson DE.   Single-dose whole pelvis megavoltage irradiation for palliative control of hematuria or ureteral obstruction.  J Urol, 1979; 122:750-51.

Bracken RB, Swanson DA, Johnson DE, and Wallace S.   Renal artery occlusion in patients with renal carcinoma.  Cancer Bulletin, 1979; 31:30-33.

Samuels MD, Moran ME, Johnson DE, and Bracken RB.  CISCA combination chemotherapy for metastatic carcinoma of the bladder.  In:  Cancer of the Genitourinary Tract: Johnson DE and Samuels MD, eds.  Raven Press, New York; 1979:101-6.

Hersh EM, Wallace S, Johnson DE, and Bracken RB.  Immunological studies in human urological cancer.  In:  Cancer of the Genitourinary Tract: Johnson DE and Samuels MD, eds.  Raven Press, New York; 1979:47-56. 

Ordonez M, Ayala AG, Gresik MV, and Bracken RB.  Primary localized amyloidosis of the male urethra (Amyloidoma).  Urology, 1979; 14(6):617-19.

Bracken RB.   Ileal conduit using midureter when pelvic ureter is compromised.  Urology, 1980; 16(2):202-3.

Paulson D, Bracken RB, Lange PH.   Problems case in transitional cell carcinoma.  In:  American Urological Association, Home Study Course, 1980; Series III: Course 2.

Henry R, Bracken RB, and Ayala AG.   Appendiceal carcinoma mimicking primary bladder cancer. J Urol, 1980; 123:590-91.

Wallace S, Chuang VP, Swanson DA, Bracken RB, von Eschenbach AC, Hersh E, and Johnson DE.   Progestogens and renal carcinoma:  Update 1980.  In:  Progestogens in the Management of Hormone Responsive Carcinomas: Tayler RW, ed.  Oxford:  The Medicine Publishing Foundation; 1980: 55-70.

DeFuria MD, Bracken RB, Johnson DE, Soloway MS, Merrin CE, Morgan LR, Miller HC, and Crooke ST.   A Phase I-II study of mitomycin C (MMC) topical therapy in low grade, low stage transitional cell carcinoma of the bladder:  An interim report.  Cancer Treat Rep, 1980;  64 (2-3):225-30.

Johnson OL, Bracken RB, and Ayala AG.  Vesical adenocarcinoma occurring in a patient with pelvic lipomatosis.  Urology, 1980; 15(3):280-2.

Bracken RB, Johnson DE, von Eschenbach AC, Swanson DA, DeFuria MD, and Crooke ST.   Role of intravesical mitomycin C in the management of superficial bladder tumors.  Urology, 1980; 16:11-15.

Bracken RB and Smith KD.   Is semen cryopreservation helpful in testicular cancer?  Urology, 1980; 15(6):581-83.

Bracken RB, Henry R, and Ordonez N.  Primary carcinoma of the male urethra.  South Med J, 1980; 73(8):1003-5.

Bracken RB.  Cancer of the testis, penis and urethra:  The impact of therapy on sexual function.  In:  Sexual Rehabilitation of the Urologic Cancer Patients: von Eschenbach AC and Rodriguez DB, eds.  G.K. Hall, Boston; 1981:108-27.

Wallace S, Chuang VP, Swanson DA, Bracken RB, Hersh EM, Ayala AG, and Johnson DE.   Embolization of renal carcinoma: Experience with 100 patients.  Radiology, 1981; 138:563-70.

Bracken RB, McDonald MW, and Johnson DE.   Complications of single stage radical cystectomy and ileal conduit.  Urology, 17:141-46.

Swanson DA, von Eschenbach AC, Bracken RB, and Johnson DE.   Salvage cystectomy for bladder carcinoma.  Cancer, 1981; 47: 2275-79.

Babaian RJ, Johnson DE, and Bracken RB.   Complications of transabdominal retroperitoneal lymphadenectomy.  Urology, 1981; 17:126-28.

Bracken RB.   Genitourinary cancer.   In:  Cancer and Chemotherapy: Crooke ST, and Prestoako A, eds.  Academic Press, New York, 1981; Vol. II:199-242.

Bracken RB, McDonald MW, and Johnson DE.   Cystectomy for superficial bladder cancer.  Urology, 1981; 18:459-63.

Thomas JL, Bernandino MD, Bracken RB.   Staging of testicular carcinoma: Comparison of CT and lymphangiography.  AJR, 1981; 137: 991-96.

Morris EJ, Bracken RB, Hopfer RL, Mills K, and Rodriguez DB.   Urinary findings in twenty asymptomatic patients with an ileal conduit.  J Enterostomal Ther, 1982;  24-27.

Ordonez N, and Bracken RB.  Hemangiopericytoma of the kidney. Urology, 1982; 19:417-19.

Johsnon DE, Bracken RB, and von Eschenbach AC.   Tumors of the male genital organs.  In:  Surgical Oncology:  Copeland EM, III, ed.  John Wiley and Sons, New York; 1982:September.

Bracken RB.   Exenterative surgery for posterior urethral cancer. Urology, 1982; 248-51.

Bracken RB.   Radical exenterative surgery.   In:  Genitourinary Tumors:  Fundamental Principles and Surgical Techniques:  Johnson DE and Boileau, eds.   Grune & Stratton, Inc., New York, 1982; 23:249-54.

Bracken RB, Sutow WW, Jaffe N, Ayala AG, and Guarde L.   Preoperative chemotherapy for Wilms' tumor.  Urology, 1982; 19:55-60.

Larson DL, and Bracken RB.  Use of the gracilis musculocutaneous flap in urologic cancer surgery.  Urology, 1982; 19:148-51.

Bracken RB.   Mitomycin C in superficial bladder cancer.  In:  Mitomycin C:  Current Impact On Cancer Chemotherapy:  Ogowa M, Rozencweig M, and Staquet MJ, eds.  Excerpta Medica, Amsterdam, 1982;. 135-42.

Bracken RB, Johnson DE, Frazier OH, Logothetis CJ, Trindale A, Samuels ML  The role of surgery following chemotherapy in Stage III germ cell neoplasms.  J Urol, 1983;  129:39-43.

Daly JM, Massar E, Copeland EM, Johnson DE, Bracken RB, Samaan M, Barlow AS, Dudrick SJ.  Adaption to amino acid infusion in surgical patients.  Surgery, 1983; 93:512-17.

Guarda LA, Ayala AG, Jaffe N, Sutow WW, and Bracken RB.  Chemotherapeutic-induced histologic changes in Wilms' tumors.  J Ped Path, 1984; 2:197-206.

Hallet MB, Weiss MA, Aron BS, and Bracken RB.   Secondary renal osteogenic sarcoma fourteen years after primary therapy. J Urol, 1984;  132:752-55.

Kaplan LA, WeiChen I, Sperling M, Bracken RB, Stein EA.   Clinical utility of serum prostatic acid phosphatase measurement for detection (screening) for diagnosis and therapeutic monitoring of prostatic carcinoma.  Am J Clin Path, 1985; 84:334-39.

Bracken RB, and Kinder B.   Intubated cutaneous ureterostomy:   An option for high risk patients needing supravesical urinary diversion. Urology, 1985; 25:45-48.

Bracken RB.   Care of the terminally ill patient with prostate or vesical cancer.  Urology Times, 1987.

Gianis TJ, Carey PM, and Bracken RB.   Giant desmoid tumor of the abdominal wall masquerading as recurrent testicular cancer.   J Urol, 1987; 138:152-53.

Bracken RB, and Heaton CL.   Erythroplasias of queyrat and balanitis xerotica obliterans.  In:  Current Therapy in Genitourinary Surgery.  B.C. Decker, Inc. Publishers, 1987; 125-27.

Bracken RB.   Renal carcinoma:  Clinical aspects and therapy.  Seminars in Roentgenology, 1987; 22 (4):241-47.

Penn I, Moulton J, Bracken RB.   Diagnosis and management of adrenal masses: 1987 Du Pont lecture.  Can J Surgery, 1988; 31 (2):105-9.

Schwartz BR, Gregg RV, Kessler DL, and Bracken RB.   Continuous postoperative epidural analgesia:   A quantum leap in the management of postoperative surgical pain. Urology, 1989; 34:349-52.

Silbar EC, Cicmanec JF, Burke BM, and Bracken RB.  Microwave sterilization:  A method for home sterilization of urinary catheters. J Urol, 1989; 141:88-90.

Douglas C, Burke BM, Kessler DL, Cicmanec JF, and Bracken RB.   Microwave sterilization:  A practical cost effective method for sterilization of urinary catheters in the home. Urology, 1990; 35:219-22.

Burke BM, Kessler DL, Cirulli C, and Bracken RB.   A comparison of Cefmetazole and Cefoxitin for the treatment of patients hospitalized with acute urinary tract infections.  J Antimicrobial Chemo, 1989;  23 (Suppl. D):35-38.

Shank RA, and Bracken RB.   Innovation in urodynamic testing:  Report of the first fully-computerized workstation. Neurourology and Urodynamics, 1990; 9:155-64.

Dodd GD III, Kaufman PN, and Bracken RB.   Duplex doppler evaluation of urinary obstruction in dogs. J Urol., 1991; 145:644-46.

Crawford ED, Smith JA, Soloway MS, Lange PH, Lynch DF, Al-Juburi A, Bracken RB, Heyden N, Bertagna C.  Treatment of stage D2 prostate cancer with Leuprolide and Anandron compared to Leuprolide and placebo.  Proceedings of the 2nd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, 1990;  61-62.

Bracken RB, Stein E, Franke K, Geller J, Pratt C, Imperato-McGinley J, Vaughan ED, Orlic S, McConnell J, Wilson J, Hill L, Roy J, Einfeldt S, Tenover L, Zeitner M, Stoner E, Pappas F, and Gregg H.  The clinical effects of a 5 alpha-reductase inhibitor, Finasteride, on benign prostatic hyperplasia.  J Urol., 1992; 147:1298-1302.

Bracken RB, and Coldiron BM.   Drawing new conclusions about squamous cell carcinoma of the penis.  Contemporary Urology, 1990; 3:23-28.

Bracken RB and Sheldon CA. Transureteroureterostomy, psoas hitch and boari flap procedures.  In:  Mastery of Surgery: Urology.  Little, Brown & Co., Boston, MA; 1991.

Lian CJ and Bracken RB.  Urinary catheter sterilization with microwave oven:  International Urogynecological Journal, 1991; 2:94-97.

The MK-906 (Finasteride) Study Group.    One-year experience in the treatment of benign prostatic hyperplasia with Finasteride  J Andrology, 1991; 12:372-75.

Soloway M, Adams G, Klimberg IL, Bracken RB, Appell R, Achari R, Henry D, and Laddu A.  Efficacy, dose-response and safety of terazosin in patients with symptoms of benign prostatic hyperplasia:  Submitted to:   Arch Int Med, April, 1992.

Bracken RB and Heaton C.  Erythroplasia of queyrat and balanitis xerotica obliterans. In:  Current Therapy in Genitourinary Surgery. B.C. Decker, Inc., Philadelphia, PA, 1992.

Gromley G, Glenn JF, and the Finasteride Study Group.  A double blind placebo controlled phase III study of Finasteride in the treatment of men with benign prostatic hyperplasia.  N Eng J Med, 1992; October:44-55.

Gromley G, and the Finasteride Study Group.  The effect of finasteride in men with benign prostatic hyperplasia.  N Engl J Med, 1992; 327:1185-91.

Stoner E, Grino P, Guess H, and The Proscar Study Group.   Five alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.  In:  Reproductive Issues and the Aging Male. Embryonics, Inc., New York, NY,  1992.

Stoner E,  and the Finasteride Study Group.  The clinical effects of 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol, 1992; 47:1298-1302.

The Finasteride Study Group.  Finasteride (MK-906) in the treatment of benign prostatic hyperplasia.  The Prostate, 1993; 22:291-99.

Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hann L, Bracken RB, Brisset JM, Calais da Silva F, Chisholm G, Crawford E, Debruyne FMJ, Dijkman GD, Frick J, Goedhals L, Knonagel H, Venner P.  Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.  J Urol, 1993; 149:77-83.

Hedden RJ, Husseinzadeh N, and Bracken RB.  Bladder sparing surgery for locally advanced female urethral cancer.  J Urol, 1993; 150:1135-37.

Tricoli JV, Yao JL, D-Souza SA, and Bracken RB.   Detection of sex-region Y (SRY) transcripts in human prostate adenocarcinoma and benign prostatic hypertrophy (BPH).  Genes Chromosomes and Cancer, 1993; 8:28-33.

Tricoli JV and Bracken RB.   ZFY gene expression and retention in human prostate adenocarcinoma.  Genes Chromosomes and Cancer, 1993;  6:65-72.

Bracken RB and Davis NS.  Management of testicular cancer.   In: Mediguide to Urology.  Lawrence DellaCorte Publications, Inc., 1993; Volume 6, Issue 6.

Bracken RB.  Management of carcinoma in the penis, urethra and scrotum in the elderly.  In: Geriatric Urology:  O'Donnell P, Ed.  Boston: Little, Brown and Company, 1994.

Bracken RB.   Urologic neoplasms: Urethra.  Accepted by: Atlas of Surgical Oncology.  Orlando, Florida: W.B. Saunders Company, 1993.

Stoner E,  and the Finasteride Study Group.   Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia.  Archives Intern Med, 1994; 154:83-88.

Stoner E, and the Finasteride Study Group:  Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.  Urology, 1994; 43:284-294.

Grino P, Stoner E, and the Finasteride Study Group.  Finasteride for the treatment and control of benign prostatic hyperplasia:  Summary of Phase III Controlled Studies. Eur Urol, 1994; 25 (suppl 1):24-28.

Bracken RB.  Surgical management of urethral carcinoma.  Atlas of Surgical Oncology, 1995; 638-47. 

Bejarano P, Nestok B, Bracken RB. Collagen a new cause for mass in the prostatic fossa after radical prostatectomy. Journal of Urologic Pathology, Volume 4, 1; 99-105.

Girman CJ, Kolman C, Liss CL, Bolognese JA, Binkowitz BS, Bracken RB, and Stoner E,  for the Finasteride Study Group.  Effects of Finasteride on health-related quality of life in men with benign prostatic hyperplasia.  The Prostate, 1995.

Moore E, Bracken B, Bremner W, Geller J, Imperato-McGinley J, McConnell J, Roy J, Tenover L, Vaughan D, Pappas F, et al. Proscar: five-year experience. European Urology, 1995;28 (4):304-309. 

Davis N, Bracken RB.  Excision and reanastomosis for bulbous urethral stricture: an unappreciated cure. Contemporary Urology, March 1997:13-21.

Bracken RB, Davis N, Mardovin W. Commentary-Transitional Cell Carcinoma of the Urethra. Seminars in Urologic Oncology, 1997; 15(2):99-104.

Bracken RB and Reising JM. Renal Cell Carcinoma, Chapter 151, Masters of Surgery, 3rd Edition, 1997:1635-1645.

Bracken RB with PLESS Study Group included in Publication.  Finasteride Decreases BPH-Related Surgery and Acute Urinary Retention. The New England Journal of Medicine, 1998; 338(9):557-563.

Bracken RB with PLESS Study Group included in Publication.  Treatment with Finasteride Preserves Usefulness of Prostate-Specific Antigen in the Detection of Prostate Cancer:  Results of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.  Submitted to Urology.

Bracken RB with PLESS Study Group.  Does Long-Term Finasteride (Proscar) Affect the Histology of Benign Prostate Tissue and Prostate Cancer on Needle Biopsy?

Bracken RB with The North American Finasteride Study Group.  Efficacy of Finasteride Is Maintained in Patients With Benign Prostatic Hyperplasia Treated For 5 Years.  Published in Urology, September, 1999; 53:690-95.

Bracken RB with PLESS Study Group included in Publication.  Effect of Finasteride on the Degree that Symptoms Bother Men and Other Health-Related Aspects Associated with Benign Prostatic Hyperplasia.  Submitted to Journal of Urology.

Bracken RB with the PLESS Study Group included in Publication.  Serum Prostate-Specific Antigen and Prostate Volume Predict Long-Term Changes in Symptoms and Flow Rate:  Results of a Four-Year, Randomized Trial Comparing Finasteride Versus Placebo. Published in Urology, October, 1999; 54:662-69.

Bracken RB with the PLESS Study Group included in Publication.  The Impact of Baseline Symptom Severity on Future Risk of BPH-Related Outcomes and Long-Term Response to Finasteride.

Bracken RB with the PLESS Study Group included in Publication.  Effect of Finasteride on Bother and Other Health-Related Quality of Life Aspects Associated with Benign Prostatic Hyperplasia.  Published in Urology, October, 1999; 54:670-78.

Bracken RB with the PLESS Study Group included in Publication.  Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in Men with Benign Prostate Hyperplasia.  Published in Urology, March, 1999; 53:581-89.

Bracken RB with the PLESS Study Group included in Publication.  Serum Prostate-Specific Antigen Concentration is a Powerful Predictor of Acute Urinary Retention and Need for Surgery in Men with Clinical Benign Prostate Hyperplasia.  Published in Urology.

Bracken RB with PLESS Study Group included in Publication.  Urinary Retention in patients with BPH Treated with Finasteride or Placebo over Four Years: Characterization of Patients and Ultimate Outcomes. 

Bracken RB with the PLESS Study Group included in Publication.  Serum Prostate-Specific Antigen is a Strong Predictor of Future Prostate Growth in Men with Benign Prostatic Hyperplasia. Published in Journal of Urology.

Gravity Induced Loss of Consciousness (GLOC):  The application of –Gz acceleration to enhance recovery.  Tripp, LD, Warm, JS, Matthews, G, Chiu, PY and Bracken, RB  Southern Society for Philosophy and Psychology  2007 (submitted for publication)

Negative Acceleration and Adaptive Automation Approaches to Counter the Effect of Acceleration Induced Loss of Consciousness.  Tripp, LD, Warm, JS, Matthews, G, Chiu, PY and Bracken, RB  Human Factors and Ergonomic 2008 (submitted for publication)

Itracranial Treatment for Solitary Prostatic Adenocarcinoma Brain Metastasis is Curative”  Urology 2008

 

ABSTRACTS/PRESENTATIONS/MEDIA

Johnson K, Bracken RB.   Are angiografisk stadieindelning AV njurcancer mojligt.  Medicinsk Radiologi , 1977; 34.

Kouttab NM, von Eschenbach AC, Bowen B, Bracken RB, Johnson DE and Dmochowski L.  Search for oncornavirus-like information in human prostatic tissues.  Proceedings of the XII International Cancer Congress, 1977.

Crooke ST, Johnson DE, and Bracken RB.  A phase I- II study of Mitomycin C topical therapy in early transitional cell carcinoma of the bladder:  A preliminary report.  Proceedings AACR and ASCO, 1978; 19:321

Swanson DA, Bracken RB, von Eschenbach AC, and Johnson DE.   Salvage cystectomy for bladder carcinoma.  Proceedings of the American Radium Society's 62nd Annual Meeting, 1979; 6 (Suppl. 1):35-36.

Massar E., Daly J., Copeland E, Johnson DE, Bracken RB, Courtney E, Johnston D, Barlow A, and Dudrick SJ.  Peripheral vein complications in patients receiving amino acid dextrose solutions.  JPEN.

Cangir A, Wallace S, and Bracken RB.  Value of pedal lymphangiograms in staging of children with testicular carcinomas.  Proceedings of American Society of Cancer Research, 1979.

Stragard JJ, von Eschenbach AC, Bracken RB, and Derwinko B.   Cell kinetic profiles of prostate, kidney and bladder tumor utilizing rapid in vitro techniques.  Proceedings of the AUA's 76th Annual Meeting, Boston, 1981.

Jaffe N, Sutow WW, Bracken RB, and Johnson DE.   Inoperable Wilm's Tumor:  Impact of preoperative chemotherapy management.  Proceedings ASCO, 1982; Vol. 1:106.

Johnson DE, Bracken RB, Logothetis CJ, Trindale A, and Samuels ML.  The indications for surgery following chemotherapy for Stage III testis cancer.  Results in 70 patients.  Proceedings ASCO, 1982; Vol. I:106.

Guarda LA, Jaffe N, Sutow W, Bracken RB, Ayala AG, and Wang YM.   Inoperable Wilms' Tumor:  The impact of chemotherapy-induced pathological changes.  Proceedings ASCO, 1982; Vol. 1:120.

Guarda LA, Ayala AG, Jaffe N, Sutow WW, and Bracken RB.  Chemo-therapeutic-induced histologic changes in Wilms' Tumor.  Proceedings of the International Academy of Pathology, Boston, Massachusetts.

Bracken RB, Sutow WW, Jaffe N, Guarda L, and Ayala AG.  Preoperative chemotherapy for Wilms' Tumor.  77th Annual Meeting of the AUA, 1982, Kansas City, Missouri.

Stein EA, Kaplan LA, Schneider H, Chen IW, Bracken RB.   Prostatic acid phosphatase: Lack of clinical efficacy for screening prostatic cancer in men over 50.  Clin Chem, 1983; 29:1253.

Kaplan LA, Stein EA, Chen IW, Bracken RB.   Prostatic acid phosphatase in diagnosis and monitoring of prostatic cancer. Clin Chem, 1983; 29:1254. 

Cicmanec JF, Evans AT, Bracken RB, and Burke BM.   Comparison of Single Dose Ceftriaxone Therapy and Standard Bactrim DS Therapy for UTI.  58th Annual Meeting of American Urological Association, North Central Section, Cedar Rapids, Iowa, September 19-22, 1984.

Bracken RB.  When is Adenocarcinoma of the Prostate Malignant?  58th Annual Meeting of American Urological Association, North Central Section, Cedar Rapids, Iowa, September 19-22, 1984.

Bracken RB, Silbar E.  One Stage Excision and End-to-end Reanastomosis:  Surgery for Bulbous Urethral Strictures.  58th Annual Meeting of American Urological Association, North Central Section, Cedar Rapids, Iowa, September 19-22, 1984.

Bracken RB.   When is Carcinoma of the Bladder Malignant?  58th Annual Meeting of American Urological Association, North Central Section, Cedar Rapids, Iowa, September 19-22, 1984.

Blake RC, Bracken RB.   Hemangiopericytoma of the Penis:  A Case Report.  58th Annual Meeting of American Urological Association,  North Central Section, Cedar Rapids, Iowa, September 19-22, 1984.

Bracken RB, and Silberstein EB.   A Comparison of Bone Scan Results Between Patients with Benign Prostatic Hyperplasia and Prostate Cancer. American Urological Association Meeting, North Central Section, Atlanta, Georgia, May 13, 1985.

Stewart DW, Agee JE, Williams JD, and Bracken RB.  Wunderlich's Syndrome:  A Diagnostic Dilemma.  59th Annual Meeting of American Urological Association, North Central Section, Palm Beach, Florida, November 3-9, 1985.

Bracken RB and Kinder B.   Intubated Cutaneous Ureterostomy: Supravesical Urinary Diversion of Choice for High Risk Patients?  59th Annual Meeting of American Urological Association, North Central Section, Palm Beach, Florida, November 3-9, 1985.

Bracken RB.  Vaginal Reconstruction after Female Cystectomy.  59th Annual Meeting of American Urological Association, North Central Section, Palm Beach, Florida, November 3-9, 1985.

Burke BM, Al-Juburi AZ, Cicmanec JF, Evans AT, and Bracken RB.  Comparison of Amdinocillin-pivoxil and Cephalexin in the Treatment of Uncomplicated Urinary Tract Infections in College Age Females.  59th    Annual Meeting of American Urological Association, North Central Section, Palm Beach, Florida, November 3-9, 1985.

Cicmanec JF, Burke BM, Al-juburi AZ, Bracken RB.   A Comparative Study of Cefmetazole, a new Cephalosporin, and Cefoxitin for the Treatment of Acute Urinary Tract Infections in Hospitalized Patients. 59th Annual Meeting of American Urological Association, North Central Section, Palm Beach, Florida, November 3-9, 1985.

Burke BM, Cicmanec JF, Bracken RB, and Evans RL.  Microwave Sterilization of Urinary Catheters.  American Society of Microbiology Meeting, Washington, D.C., March 1986.

Cicmanec JF, Burke BM, and Bracken RB.  Characterization and Sterilization of Microbial Flora on Catheters Used for Intermittent Self-catheterization.  60th Annual Meeting of the North Central Section, American Urological Association, Rancho Mirage, CA, November 1986.

Cicmanec JF, Al-juburi AZ, and Bracken RB.   A Povidine Iodine Outlet Tube Barrier to Reduce Catheter-associated UTI's.  60th Annual Meeting of the North Central Section, American Urological Association, Rancho Mirage, CA, November 1986.

Bracken RB and Burke BM.   Evaluation of Koch Pouch Urodynamics and Bacteriology.  60th Annual Meeting of the North Central Section, American Urological Association, Rancho Mirage, CA, November 1986.

Bracken RB, Schwartz R, and Gregg R.   Continuous Post-operative Epidural Analgesia; A Quantum Leap in the Management of Post-operative Surgical Pain.  60th Annual Meeting of the North Central Section, American Urological Association, Rancho Mirage, CA, November 1986.

Burke BM, Cicmanec JF, and Bracken RB.   Characterization of Microbial Flora of Urinary Catheters of Patients Using Intermittent Self-catheterization.  American Society of Microbiology Meeting,  Atlanta, GA, March 1987.

Cicmanec JF, Silbar EC, Burke BM, and Bracken RB.   Microwave Sterilization:  A Practical Cost Effective Method for Home Sterilization of Urinary Catheters.  Annual Meeting, Canadian Urological Association, Banff, Alberta, Canada, June 1987.

Bracken RB and Weiss M.   Comparison of Gleason Pattern and Radical Prostatectomy Specimens.  61st Annual Meeting of the North Central Section, American Urological Association, Detroit, MI, September 1987.

Douglas CA, Bracken RB, and Burke BM.  Microwave Sterilization of Multiple Catheters for Patients Using Intermittent Self- catheterization.  61st Annual Meeting of the North Central Section, American Urological Association, Detroit, MI, September 1987.

Bracken RB, and Burke BM.  A Comparative Study of Cefmetazole, a New Cephalosporin, and Cefoxitin for the Treatment of Acute Urinary Tract Infections in Hospitalized Patients.  61st Annual Meeting of the North Central Section, American Urological Association, Detroit, MI, September 1987.

Silbar EC, Burke BM, Douglas CA, and Bracken RB.   Microwave Sterilization:  A Practical Cost Effective Method for Home Sterilization of Urinary Catheters.  National Kidney Foundation, Inc., Washington, D.C., December 1987.

Bracken RB, Douglas CA, and Tricoli JV.   Expression of IGF-II and TGF-beta mRNA in Renal and Bladder Cell Carcinoma.  NIH Workshop on Control of Renal Growth, Bethesda, MD, March 1987.

Bracken RB and Moulton JS.   Prostate Volume Determinations:  A Comparison Between MRI and Ultrasound in Patients with BPH.  Annual Meeting, American Urological Association, Boston, MA, June 1988.

Shank RA, Bracken RB, Benz SA, Barnes MA.   Computerized Urodynamics-Improved Testing and Data Analysis.  Annual Meeting, American Urological Association, Boston, MA, June 1988.

Bracken RB, Moulton JS, and Dodd G.   Prostate Volume Determinations in Benign Prostatic Hyperplasia:  A Comparison Between MRI and Three Methods of Transrectal Ultrasonic Voluming.  XXI Congress of the International Society of Urology, Buenos Aires, Argentina, South America, October 1988.

Buffington PJ, Schwartz BR, and Bracken RB.   Death:  An Avoidable Complication of Transurethral Resection of a Bladder Paraganglioma?  North Central Meeting, American Urological Association, Orlando, FL, November, 1988.

Bracken RB.   Has the Window of Curability in Prostate Cancer Been Underestimated?  North Central Meeting, American Urological Association, Orlando, FL, November, 1988.

Shank RA, Benz SA, Barnes MM, and Bracken RB.   Can Computerized Multivariable Analysis of Urodynamic Studies Diagnose Infravesical Obstruction.  North Central Meeting, American Urological Association, Orlando, FL, November 1988.

Howard M, Dykstra M, Matthews P, and Bracken RB.   Drug Reabsorption and Excretion with Continent Urinary Diversions.  North Central Meeting, American Urological Association, Orlando, FL, November, 1988.

Bracken RB, Moulton JS, and Dodd G.   Prostate Volume Determination in Benign Prostatic Hyperplasia:  A Comparison Between MRI and Three Methods of Transrectal Ultrasonic Voluming.  North Central Meeting, American Urological Association, Orlando, FL, November 1988.

Gianis JT, Schnur SL, Kessler DL, and Bracken RB.   Techniques of Vasectomy and Resultant Antisperm Antibody Production.  North Central Meeting, American Urological Association, Orlando, FL, November 1988.

Bracken RB.   Salvage Prostatectomy.  Is it Feasible?  Is It Reasonable?  Does It Help?  Annual Meeting, Canadian Urological Association, Quebec City, Quebec, June, 1989.

Kessler DL, Weiss MA, and Bracken RB.  The Effect of Unilateral Vasectomy Upon the Contralateral Testicle.  Annual Meeting, American Urological Association, Dallas, TX, May, 1989.

Shank RA, and Bracken RB.   Infravesical Obstruction by Benign Prostatic Hypertrophy-Correlation of Symptomatology, Urodynamic Findings, and Urethral Resistance.  Annual Meeting, American Urological Association, Dallas, TX, May, 1989.

Shank RA, and Bracken RB.  Objective Documentation of Infravesical Obstruction Using Urodynamic Studies.  North Central Meeting, American Urological Association, Chicago, IL, September, 1989.

Shank RA, Cirulli C, and Bracken RB.   A Retrospective Urodynamic Analysis of 265 Females with Incontinence Using Computer Processing of Data.  North Central Meeting, American Urological Association, Chicago, IL, September, 1989.

Bracken RB.   Salvage Prostatectomy.  Is it Feasible?  Is it Reasonable?  Does it Help?  North Central Meeting, American Urological Association, Chicago, IL, September, 1989.

Bracken RB.  Total Urethrectomy, Limited Vulvectomy and Vesical Diversion for Locally Extensive Carcinoma of the Female Urethra.  North Central Meeting, American Urological Association, Chicago, IL, September, 1989.

Bracken RB and The PROSCAR Study Group.  Treatment of Benign Prostatic Hyperplasia (BPH) with PROSCAR, a 5 Alpha Reductase Inhibitor.  Workshop Conference on Androgen Therapy:  Biologic and Clinical Consequences, Marco Island, FL, January, 1990.

Soloway MS, Crawford ED, Smith JA, Lange PH, Lynch DF, Al-juburi A, Bracken RB, Wise HA, Heyden N, Bertagna C.   A Randomized, Controlled Trial of Leuprolide and Anandron (LA) Versus Leuprolide and Placebo (LP) for Advanced prostate Cancer.

Tricoli JV and Bracken RB.   Expression of TGF-beta and IGF-II mRNA in Human Urological Tumors. American Urological Association Annual Meeting, New Orleans, LA, May, 1990.

Shank RA, Cirulli C, and Bracken RB.  Objective Documentation of Infravesical Obstruction Using Urodynamic Studies. American Urological Association Annual Meeting, New Orleans, LA, May 1990.

Bracken RB and Franke K.   Is PSA Related to Prostate Volume in Patients with Clinically Benign Prostatic Hyperplasia? American Urological Association North Central Meeting, Colorado Springs, CO, October 1990.

Bracken RB and Franke K.   Is There a Relationship Between Prostate Volume and Urinary Flow Rate in Patients with Benign Prostatic Hyperplasia? American Urological Association North Central Meeting, Colorado Springs, CO, October 1990.

Bracken RB.   Is Cystoscopy Still Required in the Diagnosis of Voiding Complaints in Older Males? American Urological Association North Central Meeting, Colorado Springs, CO, October 1990.

Bracken RB.   Immunosuppression, Human Papilloma Virus (HPV) and Penile Cancer. American Urological Association North Central Meeting, Colorado Springs, CO, October 1990.

Bracken RB.   Return of Continence Following Radical Retropubic Prostatectomy:  Comparison of the Catalona to a Standard Technique of Vesicourethral Anastomosis. American Urological Association North Central Meeting, Colorado Springs, CO, October 1990.

Lian CJ, Edwards M, Thee D, and Bracken RB.   Influence of Bacterial Virulence and Bladder Outlet Obstruction on Urinary Tract Infections (UTI) in Rabbits. American Urological Association North Central Meeting, Colorado Springs, CO, October 1990.

Kaufman PN, Dodd GD, and Bracken RB.  Evaluation of Urinary Obstruction in Dogs with Duplex Doppler Ultrasound. American Urological Association North Central Meeting, Colorado Springs, CO, October 1990.

Smith JA Jr., Crawford ED, Lange PH, :Lynch DF, Al-juburi A, Bracken RB, Wise HA, Heyden N, and Bertagna C.  PSA Correlation with Response and Survival in Advanced Carcinoma of the Prostate.  American Urological Association North Central Meeting, Colorado Springs, CO, October 1990.

Lian CJ and Bracken RB.  Presence of Adhesion Factors and Bladder Outlet Obstruction in Influencing UTI in Rabbits.  American Urological Association National Meeting, Toronto, May, 1991.

Bracken RB.  Can Preoperative Endocrine Therapy Reduce the Incidence of Margin-positivity and Transcapsular Penetration in Patients Treated by Radical Prostatectomy for Localized Prostate Cancer:  A Pilot Study.  American Urological National Meeting, Toronto, May, 1991.

Bracken RB.  Epidural Infusion of Bupivacaine or Morphine for Postoperative Pain Control after Intraabdominal Genitourinary Surgery.  American Urological National Meeting, Toronto, May, 1991.

Brandt MT, Bracken RB, and Kempczinski RF.   Visceral Artery Aneurysm Treatment During Urologic Cancer Surgery:  Two Case Reports and Review of the Literature.  American Urological National Meeting, Toronto, May, 1991.

Goldman P, Bracken RB, and Tricoli JV.  Human Papillomavirus Types 16 and 18 Association with Invasive Human Bladder Tumor.  American Urological National Meeting, Toronto, May, 1991.

Tricoli JV and Bracken RB.   Expression of the Regulatory Genes ZFY and ZFX in Prostate Carcinoma.  American Urological National Meeting, Toronto, May, 1991.

Fairbanks J, Bracken RB, Wacksman J, Dolan LM, and Sheldon CA.  Bilateral Testicular Tumors in a Patient with Adrenogenital Syndrome:  Case Report and Review of the Literature.  American Urological North Central Meeting, Scottsdale, AZ, November, 1991.

Brandt MT, Sheldon CA, Wacksman J, and Bracken RB.   A New Canine Model for Treating and Studying Partial ureteral Obstruction.  American Urological North Central Meeting, Scottsdale, AZ, November, 1991.

Brandt MT and Bracken RB.   Simultaneous Treatment of Urologic Malignancy and Visceral Artery Aneurysm:  Two Case Reports and Review of the Literature.  American Urological North Central Meeting, Scottsdale, AZ, November, 1991.

Maxon HR, Thomas SR, Samaratunga R, Washburn LC, Schroder LE, Moulton JS, Bracken RB, and Vespie A.   Re-188(Sn)HEDP-A New Radiopharmaceutical for the Treatment of Skeletal Metastases. The Society of Nuclear Medicine, Los Angeles, CA, June, 1992.

Bracken RB.   Is Cystoprostatectomy the Only Surgical Option for Patients with Invasive Bladder Cancer? American Urological North Central Meeting, Puerto Rico, October, 1992.

Bracken RB.   Salvage Prostatectomy:  A Ten-year Experience.  American Urological North Central Meeting, Puerto Rico, October, 1992.

Stoner E, and the Finasteride Study Group.  Four Years Clinical Experience with Finasteride in the Treatment of Symptomatic Benign Prostatic Hyperplasia.  Xith EAU Congress Scientific Secretariat, Berlin, 1994.

Al-khafaji B, Redmond K, Bracken RB, and Nestok BR.   Persistent Prostatic Adenocarcinoma (PA) After Radiation Therapy: An Immunohistochemical Comparison with Benign Irradiated Prostates and Nonirradiated PA.

Beam T, Bracken RB, Noffsinger A, P53 and BCL-2: Potential Markers for Aggressive Bladder Cancer?,  American Urological North Central Meeting, Tuscon, Arizona, 1996.

Moayed A, Bracken RB, Frankl N, Time to Continence After Radical Retropubic Prostatectomy, American Urological North Central Meeting, Tucson, Arizona, 1996.

Bracken RB,  The Long-Term Effects of Finasteride on BPH:  Results of a Four-Year, Placebo-Controlled Study, Societe Internationale d'Urologie Meeting, Montreal, Canada, 1997.

Bracken RB, Baseline Symptoms Determine Long-term Symptomatic Response to Finasteride:  Results of a Four-Year, Placebo-Controlled Trial, European Association of Urology Congress, Barcelona, Spain, March 24, 1998.

Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson P, Malek G, Schellhammer P, Bruskewitz R, Matsumoto A, Harrison LH, Fuselier H, Walsh F, Roy J, Andriole G Resnick M and Waldstreicher J for the PLESS Study Group.  Serum Prostate-Specific Antigen is a Strong Predictor of Future Prostate Growth in Men with Benign Hyperplasia.  American Urological Association Meeting, San Diego, California, 1998.

K. Gaitonde, R.B. Bracken, M. Heiland, J.F. Donovan, Absorbable Clips As a Suturing Aid During Urethrovesical Anastomosis In Laparoscopic Radical Prostatectomy.  (Poster) International World congress of Endourology SWL Amsterdam The Netherlands August 2005.  North Central Section of the American Urological Association, Chicago, IL September 2005.

K. Gaitonde, L. Nelson, R.B. Bracken, J.F. Donovan “Nerve Sparing” Modification of Trendelenberg Position during Robotic Laparoscopic Radical Prostatectomy (RLRP):  The X-Restraint.  (Poster)  North Central Section of the American Urological Association.  September 2005.

R.B. Bracken, Prostate Cancer, diagnosis, imaging, natural history and endocrine therapy.  Speaker/Organizer and Originator  December 6, 2005 University of Cincinnati Prostate Cancer Working Group Symposium.

R. B. Bracken, Clinically Insignificant Disease?  Speaker/Organizer and Originator June 21, 2006 University of Cincinnati Prostate Cancer Working Group Symposium.

Rhoades Torre, Bracken Bruce Squamous Cell Carcinoma of the penis, University of Cincinnati Genitourinary Tumor Board, Cincinnati, Ohio June 2006 (Presentation)

RB. Bracken, “HPV in Men”. Interview with the Cincinnati Enquirer, March, 15,2007

Time To Continence After Radical Prostatectomy-Comparison Between Open Surgery And Robot Assisted Laparoscopic Radical Prostatectomy (RALRP). Gaitonde K, Frankl N, Bianchi G, Donovan JF, Bracken RB. Poster presentation at the World Congress of Endourology, Cleveland, Ohio, USA in August 2006

A Novel Technique For Ureteral Stent Placement Prior To Bladder Neck Reconstruction During Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP). K. Gaitonde, GD.Bianchi, RB. Bracken, JF. Donovan. Poster presentation at the World Congress of Endourology, Cleveland, Ohio, USA in August 2006

Unusual Complication During Robot Assisted Laparoscopic Radical Prostatectomy (RALRP) K. Gaitonde, GD.Bianchi, RB. Bracken, JF. Donovan. Poster presentation at the World Congress of Endourology, Cleveland, Ohio, USA in August 2006

Brachial-“Nerve Sparing” Modification Of Trendelenberg’s Position During Laparoscopic Radical Prostatectomy (LRP): The X-Restraint. Gaitonde K, Nelson L, Bracken RB, Donovan JF. Poster presentation at the World Congress of Endourology, Cleveland, Ohio, USA in August 2006

Time To Continence After Radical Prostatectomy-Comparison Between Open Surgery And Robot Assisted Laparoscopic Radical Prostatectomy (RALRP). Gaitonde K, Frankl N, Bianchi G, Donovan JF, Bracken RB. Accepted for presentation at the NCS AUA conference, San Diego, California, USA September 2006

HPV can threaten boys too The Cincinnati Enquirer media interview by reporter Peggy O’Farrell.  March 28, 2007

Gravity Induced Loss of Consciousness (GLOC):  The application of –Gz acceleration to enhance recovery.  Tripp, LD, Warm, JS, Matthews, G, Chiu, PY and Bracken, RB  Southern Society for Philosophy and Psychology Atlanta GA.  April 2007

Negative Acceleration and Adaptive Automation Approaches to Counter the Effect of Acceleration Induced Loss of Consciousness.  Tripp, LD, Warm, JS, Matthews, G, Chiu, PY and Bracken, RB  Human Factors and Ergonomic Society Annual Meeting October 2008 (submitted)

 

GRANTS AWARDED

Genetic Loci Associated with Prostate Cancer Development. Awarded: 5/92.  5% Co-Investigator: R. Bruce Bracken, M.D.

A Pharmacology Based Efficacy Trial of Intravesical Mitomycin-C in Bladder Cancer and Interactive Pharmacology Studies.  1996-1998, NIH Grant Sub-investigator.

 

CLINICAL STUDIES
R. Bruce Bracken, Principal Investigator

A Comparative Study of Mezlocillin Sodium (Mezlin) and Cefotaxime Sodium (Claforan) for Prophylaxis in Patients Undergoing Genitourinary Surgery.  1982-1984, Miles Pharmaceuticals

Randomized Comparison of Bactrim IV Infusion with Cefazolin and No Treatment as Prophylaxis in Trans-urethral Prostatectomy.  1984-1985, Hoffmannn LaRoche Inc.

Comparison of Amdinocillin-pivoxil Three Days of Therapy Versus Seven Days of Therapy with Cephalexin in the Treatment of Uncomplicated Urinary Tract Infections.  1984-1986, Hoffmann LaRoche Inc.

Evaluation of Amdinocillin-pivoxil Used Concomitantly with Another Beta-Lactam Antibiotic in the Treatment of Complicated and/or Recurrent Urinary Tract Infections.  1984-1987, Hoffmann LaRoche Inc.

Comparison of Amdinocillin-pivoxil Versus Cephalexin in the Treatment of Complicated Urinary Tract Infections.  1984-1987, Hoffmann LaRoche Inc.

A Study of the Safety and Clinical Efficacy of the Parenteral Administration of Cefmetazole for the Treatment of Acute Urinary Tract Infections in Hospitalized Patients.  1984-1987, Upjohn Company.

Parenteral Amdinocillin in the Treatment of Urinary Tract Infections in Patients with Impaired Kidney Function.  1985-1986, Hoffmann LaRoche Inc.

A Randomized, Double-blind, Comparative, Multi-center Study of the Safety and Efficacy of CL 284,635 Versus Amoxicillin in the Treatment of Acute Urinary Tract Infections.  1985-1988, American Cyanamid Company/Lederle Laboratories.

The Clinical Evaluation of a Percutaneous Nephrostomy Catheter.  1985-1986, The Kendall Company.

A Comparison of the Curity Retrograde Contamination Guard (RCG) Urinary Drainage System to the Curity Premium Foley Tray in the Reduction in the Rate of Urinary Tract Infection.  1985-1986, The Kendall Company.

A Randomized, Open-label, Comparative, Multi-center Study of the Safety and Efficacy of the Capsule Versus the Tablet Formulation of Cefixime (CL 284,635) Versus Amoxicillin Capsules in the Treatment of Acute Urinary Tract Infections.  1986-1988, American Cyanamid Company/Lederle Laboratories.

An 18 Month Double-blind, Controlled Study to Compare the Efficacy and Safety of the Antiandrogen RU23908 in Combination with Orchiectomy with that of Orchiectomy Alone in Patients with Stage D Carcinoma of the Prostate, Followed by an Extension Period to Evaluate the Long Term Safety and Tolerance of RU23908.  1986-1991, G.H. Besselaar and Associates.

An 18 Month Double-blind, Controlled Study to Compare the Efficacy and Safety of the Antiandrogen RU 23908 in Combination with Leuprolide with that of Leuprolide Alone in Patients with Stage D2Carcinoma of the Prostate, followed by an Extension Period to Evaluate the Long Term Safety and Tolerance of RU 23908, 1987-1996, G. H. Besselaar and Associates.

An Evaluation of Two Doses of RO 23-6240 in the Treatment of Complicated and Recurrent Urinary Tract Infections, 1987-1987 Hoffmann La Roche Inc.

A Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerance of MK-906 and the Effect of MK-906 on Prostate Volume in Patients with Benign Prostatic Hypertrophy, 1987-1991 Merck, Sharp, and Dohme, Inc.

An Open Extension of the Study to Investigate the Safety and Tolerance of MK-906 and the Effect of MK-906 on Prostate Volume in Patients with Benign Prostatic Hypertrophy, 1988-1990,  Merck, Sharp and Dohme, Inc.

A Double-blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Low Doses of MK-906 on Prostate Volume, Symptoms, and Uroflow in Patients with Benign Prostatic Hypertrophy.  1988-1990, Merck, Sharp and Dohme, Inc.

An Open Extension of the Double-Blind Study to Investigate the Safety, Tolerability and Efficacy of Low Doses of MK- 906 on Prostate Volume, Symptoms and Uroflow in Patients with Benign Prostatic Hypertrophy, 1989-1990, Merck, Sharp and Dohme, Inc..

A Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety, Tolerability, and Efficacy of MK- 906 in Patients with Benign Prostatic Hyperplasia, 1988-1990,  Merck, Sharp and Dohme, Inc.

An Open Extension of the Multicenter, Double-Blind Study to Investigate the Safety, Tolerability and Efficacy of MK-906 in Patients with Benign Prostatic Hyperplasia, 1989-1992, Merck, Sharp & Dohme, Inc.

RO 23-6240 (Fleroxacin) in Urinary Tract Infections.  A Randomized, Multidose, Double-blind Study versus Norfloxacin, 1988-1989, Hoffmann La Roche, Inc.

A Multicenter Placebo-Controlled, Randomized, Dose Titration Study of Once a Day Administration of Terazosin in the Treatment of the Symptoms of Benign Prostatic Hypertrophy, 1989-1992, Abbott Laboratories.

Long Term Safety and Efficacy of Terazosin Administered Once-A-Day in the Treatment of the Symptoms of Benign Prostatic Hyperplasia, 1990-1993, Abbott Laboratories.

A Double-Blind Randomized, Comparative, Multicenter Study of CI-983 vs. Trimethoprim/Sulfamethoxazole in the Treatment of Uncomplicated Urinary Tract Infections, 1991-1992, Parke-Davis.

A Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of Atamestane to Evaluate the Efficacy, Safety and Endocrinological Effects in Symptomatic Patients with Benign Prostatic Hyperplasia, 1991-1993, Berlex Laboratories.

Extended (Up To 18 Months) Double-Blind Evaluation of Atamestane and Placebo to Study the Long-Term Efficacy, Safety, and Endocrinological Effects in Patients with Benign Prostatic Hyperplasia, 1992-1993, Berlex Laboratories.

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Investigate the Long-Term Effects of Finasteride (MK-906) in Patients with Benign Prostatic Hyperplasia, 1992-1992, G.H. Besselaar and Associates/Merck, Sharp and Dohme, Inc..

Intergroup Prostate Cancer Prevention Trial (PCPT), "Chemoprevention of Prostate Cancer with Finasteride, Phase III" (SWOG-9217), Southwest Oncology Group/National Cancer Institute, 1993-2004.

A Clinical Trial Comparing the Safety and Efficacy of Alpha Blockade and Androgen Suppression for the Treatment of Benign Prostatic Hyperplasia (BPH), VA Medical Center, VA Co-op Study #359 1993-1995.

The Assessment of Health-Related Quality of Life in Patients with Stage D2 Prostate Cancer in Remission and Progression.  1995-1996, Premier Research/Schering Corporation.

A Randomized, Double-blind, Comparative Trial of Bicalutamide versus Placebo in Patients with Early Prostate Cancer. 1996-ongoing, Zeneca Pharmaceuticals.

A Randomized, Double-Blind, Placebo Controlled, Two year Parallel Group Study of the Efficacy and safety of GI 198745 0.5mg in the Treatment and Prevention of  Benign Prostate Hyperplasia.  1997-2000, Glaxo-Wellcome Pharmaceuticals.

A Randomized Placebo Controlled Study of Neoadjuvant Flutamide Monotherapy in men with Prostate Cancer Stages T1b, T1c, T2a, T2b, T2c NOMO Prior to Radical Prostatectomy:  A Pilot Study.  1997-1998, Division of Urology Research.

Questionnaire Evaluation Phase:  A Phase IIB/IV Clinical Development Program for Viagra™ (Sildenafil) for the Treatment of Male Erectile Dysfunction.  1997-1998, Pfizer Pharmaceuticals.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia.  1998,  Glaxo-Wellcome Pharmaceuticals.

An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (with Titration) Daily in Patients with the Signs and Symptoms of Benign Prostatic Hyperplasia. 1998-2000, Boehringer Ingleheim Pharmaceuticals.

A Randomized, Double-Blind, Comparative Trial of Bicalutamide (Casodex) 150 mg Versus Placebo in Combination with Castration as Second-Line Therapy for Patients with Asymptomatic Metastatic Prostate Cancer. 1998-1998, Astra-Zeneca Pharmaceuticals.

A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety and Preliminary Efficacy of Neoadjuvant Therapy with GI198745 in Subjects with Localized Prostate Cancer Undergoing Radical Prostatectomy. 1999-2000. Glaxo-Wellcome Pharmaceuticals.

A Phase III, Multicenter, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Controlled Release Darifenacin Versus Tolterodine in the Treatment of Subjects with Overactive Bladder.  2002-2003, Pfizer Pharmaceuticals.

Clinical Assessment of Artificial Catheterizable Stoma (Vesicostomy Button) for Use in Urinary Retention:  A Pilot Study.  2002-2003, Thomas E. Bell, MD and Stephen G. Bennett, MD.

A Phase III, Multicenter, Open-Label, Continuation Study of the Long-Term Safety, Toleration, Compliance and Efficacy of Controlled Release Darifenacin in Subjects with Overactive Bladder.  2002-2003, Pfizer Pharmaceuticals.

Selenium and Vitamin E Cancer Prevention Trial (SELECT-S0000).  2001-ongoing, Southwest Oncology Group/National Cancer Institute. (Grant Amount $115,000)

A multicenter, Pivotal Phase II, Two Arm Randomized Placebo-Controlled Study to Determine the Chemoprevention Efficacy and Safety of 60 mg Daily of GTX-006 Against High Grade Prostate Intraepithelial Neoplasia (PIN).  2001-2004, GTX, Inc.

A Double Blind, Randomized, Parallel Group Study of Alfuzosin 10mg OD Versus Placebo in the management of Acute Urinary Retention in Patients with a First Episode Due to BPH.  2001-2001, Sanofi-Synthelabo Pharmaceuticals.

A Phase III, Randomized, Double Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 mg Atrasentan in Men with Non-Metastic, Hormone-Refractory Prostate Cancer.  2001-ongoing, Abbott Laboratories.

A Phase III Extension Study to Evaluate the Safety of 10 mg Atrasentan in Men with Hormone-Refractory Prostate Cancer.  2001-ongoing, Abbott Laboratories.

Phase IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate Cancer in Patients with Intermediate to High Risk of Recurrence with Rising PSA Levels After Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized Disease.  2002-ongoing, Myriad Pharmaceuticals.

A Phase 3B, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Darifenacin in Subjects with Overactive Bladder.  2002-2003, Pfizer.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Effects of a Partial Alpha 1A/1L-Adrenoceptor Agonist, R0115-1240, in Women with Stress Urinary Incontinence or Mixed Urinary Incontinence.  2002-2004, Roche.

An Eight-Week, Double-Blind, Randomized, Parallel Group Design, Multicenter Study of Flomax® Capsules, 0.4 mg Daily Versus Placebo, in Female Patients with Lower Urinary Tract Symptoms (LUTS) with a Significant Component of Voiding Symptoms.  2002-2003, Boehringer Ingelheim.

A Long-Term, Open Label, Multicenter Study of Darifenacin in Subjects with Overactive Bladder.  2002-2004, Pfizer.

Open-Label Extension for Treatment of Incontinent Patients Who Have Completed an Ro 115-240 Study. 2003-2004, Hoffmann-LaRoche.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer. 2003-ongoing, Glaxo-Smith Kline.

Study of Duloxetine HCI in Women of Different Demographic Characteristics and Co_-Morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety. 2004-ongoing, Eli Lily and Company.

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Rofecoxib in Decreasing the Risk of Prostate Cancer (VIP Study).  2004-2004, Merck & Company Inc.

Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia (BPH); BPH Registry and Patient Survey. 2004-ongoing, Sanofi-Synthelabo Pharmaceuticals.

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Immunotherapy with Autologous Antigen-Presenting Cells Loaded with PA2024 (Provengeä,ACP8015)in Asymptomatic Patients with Gleason Sum <7, Metastatic, Androgen Independent Prostatic Adenocarcinoma.  Initiated 2004-ongoing.  Dendreon Corporation

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group,Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Darifenacin (7.5 mg o.d. with voluntary titration to 15 mg o.d.) in Patients aged ≥ 65 years with Overactive Bladder.  Initiated 2005-ongoing.  Novartis.

Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed with Prostate Cancer SWOG #0437 Initiated 2005-Ongoing.  Principal Investigator:  R. Bruce Bracken, MD, Sub-Investigators; James F. Donovan, Jr., MD and Thomas E. Bell, MD(Grant Amount $12,500)

A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days versus Ciprofloxacin HCL 500 mg Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.  Initiated 2005-2006.  Ortho-McNeil Pharmaceuticals, Inc. Sub Investigators:  Thomas E. Bell, MD, R. Bruce Bracken, MD, James F. Donovan, MD

Evaluation of Patients Who Have Completed More Than 180 Days of Active Treatment with Ro-115-1240.  Initiated 200502006. Hoffmann LaRoche, Inc.  Principal Investigator:  Safwat Zaki, MD Sub Investigators:  R. Bruce Bracken, MD, James F. Donovan, MD

A Randomized, Double-Blind Phase III Study to Evaluate Adjuvant cG250 Treatment versus Placebo in Patients with Clear Cell Renal Cell Carcinoma and High Risk for Recurrence.  Wilex AG. May 2006-Ongoing Principal Investigator:  R. Bruce Bracken, MD, Sub-Investigators:  James F. Donovan, Jr. MD and Thomas E. Bell, MD.

Development of a New Protocol # PC05110 for Prostate Cancer Detection Initiated Department of Defense June 2006-Ongoing.  Principal Investigator:  Shuk-Mei Ho, Ph.D., Sub-Investigators:  R. Bruce Bracken, MD and James F. Donovan, Jr., MD (Grant Amount $1,388,980.00)

Study of a Urethral Catheter Coated with Eluting Silver Salts (SUCCESS) Study Number: 6003 Sponsor: C.R. Bard, Inc., Initiated May 2007-Ongoing.  Principal Investigator: R. Bruce Bracken, MD Sub-investigators: James F. Donovan, Jr., MD, Ahmad Hamidinia, MD, and Krishnanath Gaitonde, MD

A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy  PROTOCOL NO:  XRP6976J/3503  SPONSOR: sanofi-aventis U.S.  Initiated June 2007-ongoing.  Principal Investigator:  R. Bruce Bracken, MD Sub-investigators:  Leslie Oleksowicz, MD, James F. Donovan, Jr., MD, Ahmad Hamidinia, MD, and Krishnanath Gaitonde, MD.